| 耿应泽,张 燕,王季石,赵 鹏,李艳菊,李梦醒,卢英豪.氟马替尼治疗80例慢性髓系白血病临床疗效与安全性分析[J].,2024,(22):4237-4239 |
| 氟马替尼治疗80例慢性髓系白血病临床疗效与安全性分析 |
| Analysis of Clinical Efficacy and Safety of Flumatinib in the Treatment of80 Cases of Chronic Myeloid Leukemia |
| 投稿时间：2024-04-24 修订日期：2024-05-20 |
| DOI：10.13241/j.cnki.pmb.2024.22.009 |
| 中文关键词: 慢性髓性白血病 氟马替尼 疗效 安全性 |
| 英文关键词: Chronic myeloid leukemia Flumatinib Efficacy Safety |
| 基金项目:贵州省卫生健康委员会课题研究项目（gzwjkj2020-1-079） |
|
| 摘要点击次数: 74 |
| 全文下载次数: 53 |
| 中文摘要: |
| 摘要 目的：分析氟马替尼治疗慢性髓性白血病（CML）的临床疗效与安全性。方法：选取80例CML患者的临床资料，观察患者治疗后3个月、6个月、12个月完全血液学缓解（CHR）、主要分子学反应（MMR）、完全细胞遗传学反应(CCyR)。根据Sokal评分将患者分为低危组、中危组和高危组，分析各组最佳反应率。并记录患者不良反应情况。结果：患者治疗后3个月、6个月、12个月CHR率、MMR率、CCyR率变化趋势均有显著性意义(P＜0.05)。低危组、中危组、高危组治疗后3个月、6个月、12个月的最佳反应率差异均有显著性意义(P＜0.05)。大部分患者对氟马替尼耐受性好，主要发生为Ⅰ-Ⅲ级血液学不良反应和Ⅰ级非血液学不良反应。结论：氟马替尼治疗CML患者，疗效良好，安全性可靠，患者血液学反应、分子学反应、细胞遗传学反应较好。 |
| 英文摘要: |
| ABSTRACT Objective: To analyze the clinical efficacy and safety of flumatinib in the treatment of chronic myeloid leukemia (CML). Methods: The clinical data of 80 CML patients were selected, and complete hematologic response (CHR), major molecular response (MMR), complete cytogenetic response (CCyR) were observed at 3 months, 6 months and 12 months after treatment. Patients were divided into low risk group, medium risk group and high risk group according to the Sokal score, and the optimal response rate in each group was analyzed. The adverse reactions of patients were recorded. Results: There were significant differences in CHR rate, MMR rate and CCyR rate at 3 months, 6 months and 12 months after treatment(P<0.05). There were significant differences in the optimal response rate between the low risk group, the middle risk group and the high risk group at 3 months, 6 months and 12 months after treatment(P<0.05). Most patients had good tolerance to flumatinib, the main adverse reactions were grade I-III hematological adverse reactions and grade I non-hematological adverse reactions. Conclusion: Flumartinib has a good therapeutic effect and reliable safety in the treatment of CML patients. The patient has good hematological response, molecular response, and cytogenetic response. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
